Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?

References

• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–2590.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438–447.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980;302:1347–1349.
   PubMed Web of Science ®Google Scholar
• Alexanian R. Localized and indolent myeloma. Blood 1980;56: 521–525.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. Prognosis of asymptomatic multiple myeloma. Arch Intern Med 1988;148:1963–1965.
   PubMed Web of Science ®Google Scholar
• Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20:1625–1634.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365:474–475.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013;27:947–953.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226–235.
   PubMedGoogle Scholar
• Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655–1665.
   Google Scholar
• San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853–1856.
   PubMed Web of Science ®Google Scholar
• Mateo Manzanera G, San Miguel Izquierdo JF, Orfao de Matos A. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5–24.
   PubMedGoogle Scholar
• Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586–2592.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Kyle RA, O’Fallon WM, et al. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994;87:266–272.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013;27:680–685.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–817.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378–3383.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111: 785–789.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941–946.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28: 1606–1610.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau, H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma:cytogenetic abnormalities [t(4;14), del (17p), 1q gains] play a major role in defining long term survival. J Clin Oncol 2012;30:1949–1952.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940–948.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005;23:6339–6344.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in-situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–1732.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013;27:1738–1744.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy and tumor load. J Clin Oncol 2013;31:4325–4332.
   PubMed Web of Science ®Google Scholar
• Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012;119:2100–2105.
   PubMed Web of Science ®Google Scholar
• Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013;54:2215–2218.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123:78–85.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–1127.
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma:the importance of as unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909–1914.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma:final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011;52:771–775.
   PubMed Web of Science ®Google Scholar
• Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Eur J Haematol 1993;50:95–102.
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Br J Cancer 2000;82:1254–1260.
   PubMed Web of Science ®Google Scholar
• Martín A, García-Sanz R, Hernández J, et al. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumor effect. Br J Haematol 2002;118:239–242.
   PubMed Web of Science ®Google Scholar
• Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113:1588–1595.
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009;84:114–122.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15:1274–1276.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775–779.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012;120:1597–1600.
   PubMed Web of Science ®Google Scholar
• Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349–355.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proc 2013;88:360–376.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035–2042.
   PubMed Web of Science ®Google Scholar
• Mateos MV, San Miguel JF. Treatment for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:1764–1765.
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175–187.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471: 467–472.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Haaber J, Dahl IM, et al. Identification of translocation products but not K-RAS mutations in memory B cells from multiple myeloma patients. Haematologica 2010;95:1730–1737.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296–303.
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL, Brents LA, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996;88:674–681.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260–264.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025–3034.
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457–4463.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001;98:217–223.
   PubMed Web of Science ®Google Scholar
• Walker B, Leone PE, Chiecchio L, et al. A compedium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56–e65.
   PubMed Web of Science ®Google Scholar
• Corradini P, Inghirami G, Astolfi M, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 1994;8:758–767.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115–130.
   PubMed Web of Science ®Google Scholar
• Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and KRAS2 activating mutations in multiple myeloma and primary plasma cell leukaemia at diagnosis. Hum Mutat 2001;18:212–224.
   PubMed Web of Science ®Google Scholar
• Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313–325.
   PubMed Web of Science ®Google Scholar
• Cremer FW, Kartal M, Hose D, et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet Cytogenet 2005;161:116–124.
   PubMed Web of Science ®Google Scholar
• Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060–1066.
   PubMed Web of Science ®Google Scholar
• Boyd KD, Ross FM, Tapper WJ, et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 2011;50:765–774.
   PubMed Web of Science ®Google Scholar
• Zangari M. Effect of low dose bortezomib on bone formation in smoldering myeloma patients. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Institutes of Health; 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00983346?
   Google Scholar
• Hardman WE. Inhibition of nuclear factor kappa B for prevention of disease progression in indolent B cell malignancies. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Institutes of Health; 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00899353?
   Google Scholar
• Munshi N. Multicenter phase II study on the anti-tumor activity, safety and pharmacology of two dose regimens of IPH2101, a fully human monoclonal anti KIR antibody, in patients with smoldering multiple myeloma (KIRMONO). ClinicalTrials.gov [Internet]. Bethesda, MD: US National Institutes of Health; 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01222286?
   Google Scholar
• Lonial S. Lenalidomide or observation in treating patients with asymptomatic high risk smoldering multiple myeloma. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Institutes of Health; 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01169337?term
   Google Scholar
• Golombick T, Diamond TH, Manoharan A, et al. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol 2012;87:455–460.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Kuehl M, Balakumara A, et al. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 2010;10: 248–257.
   PubMed Web of Science ®Google Scholar